Please wait while the search results are loading...

Biotech and Orphan Drugs Create New Revenues for Drug Firms, Business and Industry Trends Analysis

Many biotech companies have focused on developing drugs for relatively small patient populations.  For example, biotech pioneers Genentech and Biogen Idec developed Rituxan for the treatment of non-Hodgkin’s lymphoma, an important but relatively small market.
Drugs such as Rituxan are commonly referred to as “orphan drugs,” which means that they treat illnesses that no other drug on the market addresses, which are needed by relatively small patient populations.  Technically, a drug designated by the FDA with orphan status provides therapeutic benefit for a disease or condition that affects less than 200,000 people in the U.S.  These drugs enjoy a unique status due to the Orphan Drug Act of 1983, which gives pharmaceutical companies a seven-year monopoly on the drug without having to file for patent protection, plus a tax credit for research and development costs.  


A Representative List of Organizations that Have Used our Research and Products:



Testimonials

I’m amazed at how much information is available and the various ways to access it. This will be a major resource for our serious job seekers.

Career Services, Penn State University

Plunkett Research Online provides a great ‘one stop shop’ for us to quickly come up to speed on major industries. It provides us with an overall analysis of the market, key statistics, and overviews of the major players in the industry in an online service that is fast, easy to navigate, and reliable.

Wendy Stotts, Manager, Carlson Companies

I really appreciate the depth you were able to get to so quickly (for our project). The team has looked through the material and are very happy with the data you pulled together.

Hilton Worldwide, Marketing Manager
Real Time Web Analytics preload imagepreload image